Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 12/20 | 0.42 |
| ▸ | DPP8 | Q6V1X1 | 5/20 | 0.42 |
| ▸ | DPP9 | Q86TI2 | 4/20 | 0.42 |
| ▸ | FAP | Q12884 | 1/20 | 0.41 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.41 |
| ▸ | NOS2 | P35228 | 2/20 | 0.38 |
| ▸ | NOS3 | P29474 | 1/20 | 0.38 |
| ▸ | NOS1 | P29475 | 1/20 | 0.38 |
| ▸ | PRCP | P42785 | 1/20 | 0.34 |
| ▸ | ANPEP | P15144 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4963191 | 0.98 | DPP4 (0.41) | DPP4DPP8DPP9FAPDPP7 | |
| SCHEMBL10905658 | 0.86 | DPP4 (0.39) | DPP4DPP8DPP9FAPDPP7 | |
| SCHEMBL28071490 | 0.86 | DPP4 (0.53) | DPP4DPP8DPP9FAPDPP7 | |
| Hydrochloric Acid SCHEMBL28071357 | 0.85 | DPP4 (0.51) | DPP4DPP8DPP9FAPDPP7 | |
| SCHEMBL28407251 | 0.84 | DPP4 (0.36) | DPP4DPP8DPP9FAPDPP7 | |
| SCHEMBL6859669 | 0.76 | NOS2 (0.46) | DPP4DPP8DPP9FAPDPP7 | |
| SCHEMBL995604 | 0.76 | NOS2 (0.46) | DPP4DPP8DPP9FAPDPP7 | |
| SCHEMBL146828 | 0.76 | NOS2 (0.46) | DPP4DPP8DPP9FAPDPP7 | |
| SCHEMBL195277 | 0.75 | DPP4 (0.35) | DPP4DPP8DPP9FAPDPP7 | |
| SCHEMBL464808 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240209353-A1 | NADK2 INHIBITION IN CANCER AND FIBROTIC DISORDERS | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2024-06-27 | — | — | US | disclosed |
| EP-4319766-A1 | NADK2 INHIBITION IN CANCER AND FIBROTIC DISORDERS | Memorial Sloan Kettering Cancer Center (US) | 2024-02-14 | — | — | EP | disclosed |
| WO-2022216903-A1 | NADK2 INHIBITION IN CANCER AND FIBROTIC DISORDERS | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2022-10-13 | — | — | WO | disclosed |
| WO-2021180063-A1 | METHODS FOR DETECTING AND QUANTIFYING BIOLOGICAL MODIFICATIONS IN ANTIBODIES | I-MAB BIOPHARMA CO., LTD. (CN) | 2021-09-16 | — | — | WO | disclosed |
| US-10266565-B2 | Peptide mimetic ligands of polo-like kinase 1 polo box domain and methods of use | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES (US) | 2019-04-23 | — | — | US | disclosed |
| US-9175038-B2 | Peptide mimetic ligands of polo-like kinase 1 polo box domain and methods of use | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES (US) | 2015-11-03 | — | — | US | disclosed |
| US-20140142044-A1 | PEPTIDE MIMETIC LIGANDS OF POLO-LIKE KINASE 1 POLO BOX DOMAIN AND METHODS OF USE | The United States of America, as represented by the Secretary, Department of Health & Human Servic (US) | 2014-05-22 | — | — | US | disclosed |
| EP-2686342-A2 | PEPTIDE MIMETIC LIGANDS OF POLO-LIKE KINASE 1 POLO BOX DOMAIN AND METHODS OF USE | The Government of The United States of America, as represented by The Secretary, Department of Health and Human Services (US) | 2014-01-22 | — | — | EP | disclosed |
| WO-2012142245-A2 | PEPTIDE MIMETIC LIGANDS OF POLO-LIKE KINASE 1 POLO BOX DOMAIN AND METHODS OF USE | THE GOVERNMENT OF THE UNITED OF AMERIA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES (US) | 2012-10-18 | — | — | WO | disclosed |
| US-20120065146-A1 | PEPTIDE MIMETIC LIGANDS OF POLO-LIKE KINASE 1 POLO BOX DOMAIN AND METHODS OF USE | GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH (US) | 2012-03-15 | — | — | US | disclosed |
| WO-2010132869-A2 | PEPTIDE MIMETIC LIGANDS OF POLO-LIKE KINASE 1 POLO BOX DOMAIN AND METHODS OF USE | GOVERNMENT OF THE U.S.A., AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2010-11-18 | — | — | WO | disclosed |
| WO-2010015815-A2 | COMPOUNDS FOR THE TREATMENT OF FLAVIVIRAL INFECTIONS | SUMMIT CORPORATION PLC (GB) | 2010-02-11 | — | — | WO | disclosed |
| US-20090258394-A1 | METHOD FOR THE PRODUCTION OF HIGH-LEVEL SOLUBLE HUMAN RECOMBINANT INTERFERON ALPHA IN E. COLI AND VECTORS USEFUL FOR SUCH A PRODUCTION | INSTITUT PASTEUR (FR) | 2009-10-15 | — | — | US | disclosed |
| EP-2000480-A1 | Method for the production of high-level soluble human recombinant interferon alpha in e. coli and vectors useful for such a production | INSTITUT PASTEUR (FR) | 2008-12-10 | — | — | EP | disclosed |
| EP-1990349-A1 | Method for the production of high-level soluble human recombinant interferon alpha in E. coli and vectors useful for such a production | INSTITUT PASTEUR (FR) | 2008-11-12 | — | — | EP | disclosed |
| US-20040171074-A1 | Structures of substrate binding pockets of SCF complexes | MOUNT SINAI HOSPITAL (CA) | 2004-09-02 | — | — | US | disclosed |
| US-4578474-A | HYPOTENSIVE AGENTS | E. R. SQUIBB & SONS, INC. (US) | 1986-03-25 | — | — | US | disclosed |
| US-4497953-A | HYPOTENSIVE AGENTS | E. R. SQUIBB & SONS, INC. (US) | 1985-02-05 | — | — | US | disclosed |
| US-4390695-A | HYPOTENSIVE AGENTS | E. R. SQUIBB & SONS, INC. (US) | 1983-06-28 | — | — | US | disclosed |
| US-4310461-A | HYPTENSIVE AGENTS | E. R. SQUIBB & SONS, INC. (US) | 1982-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140142044-A1 | PEPTIDE MIMETIC LIGANDS OF POLO-LIKE KINASE 1 POLO BOX DOMAIN AND METHODS OF USE | PLK1, PLK4, PLK3 | DPP4 2126/4885DPP8 3075/4885DPP9 1774/4885 |
| US-20120065146-A1 | PEPTIDE MIMETIC LIGANDS OF POLO-LIKE KINASE 1 POLO BOX DOMAIN AND METHODS OF USE | PLK1, PLK2, PLK4 | DPP4 3507/4885DPP8 2784/4885DPP9 2569/4885 |
| US-10266565-B2 | Peptide mimetic ligands of polo-like kinase 1 polo box domain and methods of use | PLK1, POLK, POLD3 | DPP4 3132/4885DPP8 3129/4885DPP9 2359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.